1. Home
  2. NICE Guidance
  3. Conditions and diseases
  4. Cancer
  5. Head and neck cancers

Pembrolizumab with lenvatinib for untreated PD-L1 positive recurrent or metastatic squamous cell head and neck cancer [ID5118]

In development [GID-TA11005] Expected publication date: TBC

  • Project information
  • Project documents

Documents

A list of downloadable documents created during development.

Consultation on suggested remit, draft scope and provisional stakeholder list of consultees and commentators: 5118

  • Draft matrix post referral PDF 165 KB 08 June 2023  
  • Draft scope post referral PDF 172 KB 08 June 2023  

Topic selection

  • Topic selection